Summary: Evolutionary adaptations that help animals such as yaks and Tibetan antelopes survive at extreme altitudes may point to new ways to repair nerve damage in human diseases. A new study identifies a mutation in the Retsat gene—common in high-altitude species—that protects the brain from low oxygen and stimulates regeneration of the myelin sheath.
Researchers identified a vitamin A–derived metabolite called ATDR that, when supplied to mouse models, repaired nerve damage in conditions resembling multiple sclerosis (MS) and cerebral palsy. The finding suggests a natural, repair-focused strategy to restore brain function.
Key Facts
- Retsat mutation: High-altitude animals carry a variant of the Retsat gene that helps preserve brain function under chronic low-oxygen conditions.
- Myelin protection in development: Newborn mice exposed to reduced-oxygen conditions equivalent to elevations above 13,000 feet performed better on learning and memory tests when they carried the Retsat variant and showed greater myelin density.
- ATDR discovery: The Retsat variant boosts enzymatic activity that converts vitamin A into the metabolite ATDR, which promotes maturation of oligodendrocytes—the cells that form and repair myelin.
- Therapeutic potential for MS: Administering ATDR to mice with an MS-like disease reduced disease severity and improved motor function.
- Repair instead of suppression: Unlike most current MS therapies that focus on immune suppression, ATDR leverages an endogenous molecule to actively stimulate repair of damaged myelin.
Source: Cell Press
A genetic adaptation that helps high-altitude animals survive thin air may point to new treatments for myelin damage in humans.
Published March 13 in the Cell Press journal Neuron, the study reveals a naturally existing neuronal pathway that promotes remyelination after injury. By tracing an evolutionary adaptation found in plateau-dwelling species, the researchers expose a mechanism that could be harnessed to treat diseases such as multiple sclerosis or injury-related myelin loss.
“Evolution provides a wide array of genetic solutions to environmental challenges,” says corresponding author Liang Zhang of Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. “Studying naturally occurring genetic adaptations can uncover pathways that are directly relevant to human disease.”
Myelin is the insulating layer that surrounds nerve fibers in the brain and spinal cord, enabling fast and efficient electrical signaling. Insufficient oxygen during brain development can impair myelination and contribute to conditions such as cerebral palsy. In adults, myelin damage is a hallmark of multiple sclerosis and is also implicated in age-related vascular brain disorders.
Previous genetic surveys of animals living on the Tibetan Plateau—whose average elevation exceeds 14,700 feet—identified a gain-of-function variant in Retsat. Zhang and colleagues asked whether that variant could protect or restore myelin. They exposed newborn mice to hypoxic conditions approximating high-elevation oxygen levels for about a week. Mice carrying the Retsat variant showed better learning, memory and social behaviors and had noticeably higher myelin levels around nerve fibers than mice with the standard gene.
The team then tested whether the Retsat variant could accelerate repair after myelin injury. Mice with the variant recovered myelin more rapidly and more fully. Injured regions contained more mature oligodendrocytes, the cells that synthesize myelin.
Biochemical analyses revealed that the Retsat variant increases production of ATDR (all-trans-13,14-dihydroretinol), a metabolite derived from vitamin A. In neurons, ATDR is converted to all-trans-dihydroretinoic acid, which acts as a neuron-to-glia signaling molecule. That signal activates the RXR-γ pathway in oligodendrocyte progenitor cells, driving their differentiation and initiating remyelination. Direct administration of ATDR promoted remyelination in multiple mouse models of myelin injury and reduced symptoms in an MS-like disease model.
“Most current MS therapies focus on restraining immune attacks,” Zhang notes. “ATDR is a molecule already present in the body. Our results point to a complementary strategy: use endogenous signaling molecules to stimulate the cells that rebuild myelin and repair existing damage.”
Funding:
This research was supported by the National Science and Technology Major Project, the National Natural Science Foundation of China, the China Postdoctoral Science Foundation, the Shanghai Post-doctoral Excellence Program, the Natural Science Foundation of Shanghai, the 2024 Tibet Autonomous Region Science and Technology Plan Key R&D and Transformation Project, the Open Research Fund of Navy Medical University Basic Medical College, and the Yunnan Revitalization Talent Support Program.
Key Questions Answered
Q: How can a “yak gene” inform human treatments for MS?
A: Animals adapted to high altitude evolved mechanisms to protect their brain’s myelin under low-oxygen stress. The Retsat variant exposes a repair pathway—centered on ATDR production—that supports myelin maintenance and regeneration. That pathway provides a target for therapies that could stimulate repair in human myelin diseases.
Q: Is this approach just another way to suppress the immune system?
A: No. The discovery targets regeneration rather than immune suppression. It promotes differentiation of oligodendrocyte progenitors so they can rebuild the myelin sheath, offering a potential way to reverse existing damage.
Q: Could I get these benefits by taking more vitamin A?
A: Not necessarily. The benefit depends on converting vitamin A into the specific metabolite ATDR. The Retsat variant enhances that conversion in neurons. The therapeutic strategy under study is to deliver ATDR itself or mimic its signaling to the brain rather than increasing dietary vitamin A.
Editorial Notes
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full.
- Additional context was added by editorial staff.
About this genetics and neurology research news
Author: Julia Grimmett
Source: Cell Press
Contact: Julia Grimmett – Cell Press
Image credit: Neuroscience News
Original Research: Open access. “A Gain-of-Function Retsat Variant from High-Altitude Adaptation Promotes Myelination via a Neuronal Dihydroretinoic Acid-RXR-γ Pathway” by Daopeng Li et al., Neuron. DOI: 10.1016/j.neuron.2026.01.013
Abstract
A Gain-of-Function Retsat Variant from High-Altitude Adaptation Promotes Myelination via a Neuronal Dihydroretinoic Acid-RXR-γ Pathway
Studying evolutionary adaptations can reveal key regulators of biological processes. Here, a Retsat variant (Q247R) found in high-altitude species defines a central pathway controlling central nervous system myelination and repair. Mice carrying this variant show reduced hypoxia-induced neonatal hypomyelination and enhanced remyelination as adults.
The variant increases enzymatic activity, elevating neuronal production of all-trans-13,14-dihydroretinol (ATDR). ATDR is converted in neurons to all-trans-dihydroretinoic acid, which serves as a neuron-to-glia paracrine signal to activate RXR-γ in oligodendrocyte progenitor cells, stimulating their differentiation and myelination. Administering ATDR, a prodrug, strongly promotes remyelination across multiple injury models.
This work identifies Retsat and dihydroretinoids as pivotal regulators of white matter integrity and highlights an evolution-inspired therapeutic path for white matter diseases.